Literature DB >> 24609220

Diagnosis of renal tumors by in vivo proton magnetic resonance spectroscopy.

Sabina Sevcenco1, Martin Krssak, Domagoj Javor, Lothar Ponhold, Franklin E Kuehhas, Harun Fajkovic, Andrea Haitel, Sharokh F Shariat, Pascal A Baltzer.   

Abstract

PURPOSE: To evaluate the diagnostic potential of choline measurements by in vivo magnetic resonance spectroscopy (MR spectroscopy) for diagnosis of renal masses.
METHODS: Twenty-eight patients with 29 renal lesions underwent prospectively preoperative 3 T MR spectroscopy of renal masses before diagnostic tissue confirmation. A respiratory-triggered single-voxel MR spectroscopy was performed in these masses using the point-resolved spectroscopy (TR, 2,000 ms, TE, 135 ms) sequence. The spectra were analyzed for choline resonances at 3.23 ppm, which were normalized by the noise outside the diagnostic range of the spectra. Image and spectra analyses were conducted blinded to all patient-related data. Histological results of the surgical resection or image-guided biopsy specimen were defined as the standard of reference. Appropriate statistical tests were used.
RESULTS: Seventeen lesions were histopathologically malignant, and 12 lesions were benign. Mean choline SNR in malignant lesions was 2.9 and 1.33 in benign lesions (P = 0.019). ROC analysis revealed an area under the curve of 0.721 and SE 0.0763 with a P value of 0.0038. A Cho SNR ≥2 as cutoff for malignancy resulted in a sensitivity and specificity of 52.9 % (95 % CI 27.8-77.0 %) and 91.7 % (61.5-99.8 %), respectively. Although not significant, choline was observed more regularly in G3 (4 out of 5) compared with G2 (5 out of 12) RCC (P > 0.05).
CONCLUSIONS: We could demonstrate the potential role of in vivo MR spectroscopy as a tool for differentiating benign from malignant masses with a high positive predictive value of 90 %. Furthermore, choline may be a biomarker of RCC aggressiveness.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24609220     DOI: 10.1007/s00345-014-1272-y

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  23 in total

Review 1.  Management of localized and locally advanced renal tumors. A contemporary review of current treatment options.

Authors:  S Brookman-May; J F Langenhuijsen; A Volpe; A Minervini; S Joniau; M Salagierski; M Roscigno; B Akdogan; A Vandromme; O Rodriguez-Faba; M Marszalek
Journal:  Minerva Med       Date:  2013-06       Impact factor: 4.806

2.  Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy.

Authors:  Michael J Leveridge; Antonio Finelli; John R Kachura; Andrew Evans; Hannah Chung; Daniel A Shiff; Kimberly Fernandes; Michael A S Jewett
Journal:  Eur Urol       Date:  2011-06-24       Impact factor: 20.096

3.  Delayed CT to evaluate renal masses incidentally discovered at contrast-enhanced CT: demonstration of vascularity with deenhancement.

Authors:  M Macari; M A Bosniak
Journal:  Radiology       Date:  1999-12       Impact factor: 11.105

4.  Rising incidence of small renal masses: a need to reassess treatment effect.

Authors:  John M Hollingsworth; David C Miller; Stephanie Daignault; Brent K Hollenbeck
Journal:  J Natl Cancer Inst       Date:  2006-09-20       Impact factor: 13.506

Review 5.  The Heidelberg classification of renal cell tumours.

Authors:  G Kovacs; M Akhtar; B J Beckwith; P Bugert; C S Cooper; B Delahunt; J N Eble; S Fleming; B Ljungberg; L J Medeiros; H Moch; V E Reuter; E Ritz; G Roos; D Schmidt; J R Srigley; S Störkel; E van den Berg; B Zbar
Journal:  J Pathol       Date:  1997-10       Impact factor: 7.996

6.  Renal cell carcinoma: diffusion-weighted MR imaging for subtype differentiation at 3.0 T.

Authors:  Haiyi Wang; Liuquan Cheng; Xu Zhang; Dianjun Wang; Aitao Guo; Yuangui Gao; Huiyi Ye
Journal:  Radiology       Date:  2010-08-16       Impact factor: 11.105

7.  Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopy.

Authors:  Rachel Katz-Brull; Neil M Rofsky; Martina M Morrin; Ivan Pedrosa; Daniel J George; M Dror Michaelson; Robert P Marquis; Michal Maril; Carolina Noguera; Robert E Lenkinski
Journal:  Am J Physiol Renal Physiol       Date:  2004-11-30

Review 8.  Breast lesions: diagnosis by using proton MR spectroscopy at 1.5 and 3.0 T--systematic review and meta-analysis.

Authors:  Pascal A T Baltzer; Matthias Dietzel
Journal:  Radiology       Date:  2013-03-06       Impact factor: 11.105

9.  Java-based graphical user interface for the MRUI quantitation package.

Authors:  A Naressi; C Couturier; J M Devos; M Janssen; C Mangeat; R de Beer; D Graveron-Demilly
Journal:  MAGMA       Date:  2001-05       Impact factor: 2.533

10.  Localized in vivo proton spectroscopy of renal cell carcinoma in human kidney.

Authors:  D Y Kim; K B Kim; O D Kim; J K Kim
Journal:  J Korean Med Sci       Date:  1998-02       Impact factor: 2.153

View more
  4 in total

1.  In Vivo Renal Lipid Quantification by Accelerated Magnetic Resonance Spectroscopic Imaging at 3T: Feasibility and Reliability Study.

Authors:  Ahmad A Alhulail; Mahsa Servati; Nathan Ooms; Oguz Akin; Alp Dincer; M Albert Thomas; Ulrike Dydak; Uzay E Emir
Journal:  Metabolites       Date:  2022-04-23

Review 2.  [Noninvasive phenotyping of renal tumors-current state of the art].

Authors:  Hubert Stefan Bickel
Journal:  Radiologe       Date:  2018-10       Impact factor: 0.635

Review 3.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

4.  Renal carcinoma CD105-/CD44- cells display stem-like properties in vitro and form aggressive tumors in vivo.

Authors:  M Fiedorowicz; M I Khan; D Strzemecki; J Orzeł; M Wełniak-Kamińska; A Sobiborowicz; M Wieteska; Z Rogulski; L Cheda; W Wargocka-Matuszewska; K Kilian; C Szczylik; A M Czarnecka
Journal:  Sci Rep       Date:  2020-03-25       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.